Pharma Focus Asia

Kite Announces Plans to Build a New Manufacturing Industry


Kite announces plans to build industry-leading cell therapy manufacturing capabilities with a new viral vector facility in Oceanside, California.


A new state-of-the-art 67,000 square feet building will be constructed inside Gilead’s existing facility.

The new facility will manufacture the viral vectors such as replication-deficient gamma-retroviral vector PG13-CD19-H3 and replication-deficient lentiviral vector.

PG13-CD19-H3 is the important initial material used for production of Yescarta. It was the company’s first Chimeric Antigen Receptor (CAR) T-cell therapy that is used for treatment of large B-cell lymphoma in adult patients.

Yescarta extracts white blood cells (WBCs) from the patient's body and differentiate T-cells from the WBCs to modify and re-use them into patient's body to identify and kill the cancer cells.

The retroviral vector PG13-CD19-H3 is also used for development of other investigational therapies such as KTE-X19 for acute lymphocytic leukaemia and mantle cell lymphoma. The facility also supports the investigational biologic production of KITE-585 and KITE-718 therapy.


NameKite, a Gilead Company
LocationOceanside, California, USA
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference